Newborn genomes and the NHS Ten-Year Plan: visionary leap or overreach?

The recently published Ten-Year Health Plan for England outlines an ambitious vision for the future of the NHS, focusing on prevention, early intervention, and cutting-edge innovation (see BioNews 1297).

Among the most striking elements of this vision is the Government's intention to 'implement universal newborn genomic testing and population-based polygenic risk scoring,' putting genomics at the heart of a predictive, personalised health system. This move signals the UK's willingness to embrace a genomics-led transformation in healthcare, yet it also raises urgent concerns regarding ethics, science, and equity that must not be overlooked.

Universal newborn whole genome sequencing (WGS) and polygenic scores represent a significant expansion of the state's role in preemptive health screening. The aim is commendable: to detect rare but treatable genetic disorders at birth and to estimate an individual's risk of developing common, complex diseases such as diabetes, heart disease, or cancer.

The UK has already begun testing the waters with the NHS and Genomics England's Generation Study, which is offering WGS to 100,000 newborns to screen for more than 200 rare conditions (see BioNews 1172, 1210, 1259 and 1261). According to early reports, this initiative has shown great promise. For example, conditions such as metachromatic leukodystrophy can now be detected early enough to allow intervention before irreversible damage occurs.

However, while the clinical benefits of WGS for rare monogenic conditions are becoming clearer, polygenic scores are more contentious. These scores attempt to quantify disease susceptibility by analysing thousands of common genetic variants across the genome. While this approach holds considerable promise for stratifying population-level risk and identifying those who may benefit from earlier or more intensive screening, the clinical utility of polygenic scores remains limited (see BioNews 1212). Polygenic models are still under development and they often lack the predictive accuracy necessary to inform health interventions meaningfully, particularly across diverse ancestral populations.

Indeed, one of the most pressing concerns around polygenic scores is the related equity gap. Most genomic research to date has been conducted on populations of European descent. Consequently, polygenic scores perform more accurately for individuals of European ancestry, while offering lower predictive value for those of non-European ancestry (see BioNews 1293). Embedding such models into universal screening risks entrenching existing health disparities rather than improving them. Without robust efforts to diversify genomic datasets and validate polygenic scores across populations, the promise of personalised medicine will remain largely inaccessible to many.

Moreover, there are also some important ethical issues. Informed consent in the context of newborn screening is inherently complex. Babies cannot consent to testing, and parents may not fully grasp the scope, limitations, or long-term implications of genome sequencing (see BioNews 1127 and 1128). What happens to genomic data once collected? Who has access? For how long is it stored? And can the child opt out later in life? The Ten-Year Plan speaks of using data to 'drive innovation', but such ambitions must be carefully balanced against privacy, autonomy, and the need for ongoing, transparent governance.

A further complication is the risk of medicalisation and anxiety. Polygenic scores predict risk, not certainty. Telling people they are in the top percentile for developing heart disease, for example, may provoke unnecessary stress or prompt unwarranted lifestyle changes or medical interventions. There is also the possibility of creating new forms of genetic stigma or reinforcing deterministic ideas of health and identity that reduce people to their genomic profile.

These risks are particularly salient when viewed through the lens of NHS resource allocation and genomics education. Implementing universal newborn sequencing will require major investment not only in testing infrastructure but also in training a workforce equipped to interpret and communicate complex genetic information (see BioNews 1137 and 1142). Health professionals – particularly those in primary care and paediatrics – will need robust, ongoing support to incorporate genomics into clinical conversations without overwhelming families or misrepresenting risk.

This educational need cannot be overstated. Genomic literacy remains limited among healthcare workers and the public alike. Without targeted efforts to build confidence and clarity around genomics, the NHS risks rolling out a high-stakes innovation into a system unequipped to manage its implications. Resource allocation, therefore, becomes not only a financial concern but a matter of patient safety, equitable access, and ethical practice.

The Plan also refers to creating 'a new genomics population accessible to all,' but does so without addressing the long-standing inequities in NHS access to genetic testing and specialist services (see BioNews 1294). For families in underserved or underfunded areas, particularly those from marginalised communities, promises of personalised genomic care may ring hollow unless accompanied by policies that address structural inequality. Universal access must be more than a slogan – it must be a deliverable.

At a systems level, the Government's framing of this initiative as a 'big bet' within its reform agenda deserves closer scrutiny. Framing science-led health interventions as wagers may signal innovation, but it also underscores the uncertainty and potential fallout if these strategies do not deliver. Genomics should not be a gamble. It must be grounded in patient-centred care, evidence-based policy and inclusive practice.

There is also a broader philosophical question at play: what kind of healthcare future do we want? The use of polygenic scores suggests a shift toward ongoing genetic surveillance, potentially introducing new forms of state involvement in managing individual health trajectories throughout life. If left unchecked, such surveillance could evolve into a techno-bureaucratic system that prioritises risk management over individual choice and holistic care.

In its most optimistic form, the genomic turn in healthcare represents a powerful tool for health equity, early diagnosis and personal empowerment. It has the potential to reshape the NHS into a more proactive, cost-efficient, and patient-responsive system. But it can only do so if built on a foundation of trust, transparency, and fairness. Implementing universal newborn sequencing without first resolving key issues around consent, data governance, equity, workforce capacity and clinical validity risks undermining public confidence in the very system it seeks to improve.